| P2093 | author name string | Kenichi Fukumoto | |
| | Manoela V Fogaça | |
| | Ronald S Duman | |
| | Xiao-Yuan Li | |
| | Taro Kato | |
| | Rong-Jian Liu | |
| | Catharine Duman | |
| P2860 | cites work | Positive AMPA receptor modulation rapidly stimulates BDNF release and increases dendritic mRNA translation | Q24653485 |
| | Genetic variant BDNF (Val66Met) polymorphism alters anxiety-related behavior | Q24679793 |
| | Rapid antidepressant actions of scopolamine: Role of medial prefrontal cortex and M1-subtype muscarinic acetylcholine receptors | Q27308009 |
| | Antidepressant action of ketamine via mTOR is mediated by inhibition of nitrergic Rheb degradation | Q27319514 |
| | Optogenetic stimulation of infralimbic PFC reproduces ketamine's rapid and sustained antidepressant actions. | Q27328579 |
| | Automated three-dimensional detection and shape classification of dendritic spines from fluorescence microscopy images | Q28755127 |
| | The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R) | Q29547223 |
| | Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report | Q29615999 |
| | Antidepressant effects of ketamine in depressed patients | Q29617327 |
| | A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression | Q29617914 |
| | mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists | Q29618120 |
| | NMDAR inhibition-independent antidepressant actions of ketamine metabolites. | Q30370600 |
| | GLYX-13, a NMDA receptor glycine-site functional partial agonist, induces antidepressant-like effects without ketamine-like side effects | Q30440925 |
| | NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses | Q30471587 |
| | Scopolamine rapidly increases mammalian target of rapamycin complex 1 signaling, synaptogenesis, and antidepressant behavioral responses. | Q30544800 |
| | Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants | Q33604879 |
| | Brain-derived neurotrophic factor Val66Met allele impairs basal and ketamine-stimulated synaptogenesis in prefrontal cortex | Q34061150 |
| | A simple role for BDNF in learning and memory? | Q34099252 |
| | Stress-induced prefrontal reorganization and executive dysfunction in rodents | Q34139931 |
| | Identification of a low-molecular weight TrkB antagonist with anxiolytic and antidepressant activity in mice | Q34179450 |
| | Role of BDNF/TrkB signaling in antidepressant-like effects of a group II metabotropic glutamate receptor antagonist in animal models of depression | Q34308234 |
| | Neurocircuitry of mood disorders | Q34660904 |
| | Rapid and Sustained Reductions in Current Suicidal Ideation Following Repeated Doses of Intravenous Ketamine: Secondary Analysis of an Open-Label Study | Q34677398 |
| | GluN2B-containing NMDA receptors regulate depression-like behavior and are critical for the rapid antidepressant actions of ketamine | Q34729421 |
| | Glutamate N-methyl-D-aspartate receptor antagonists rapidly reverse behavioral and synaptic deficits caused by chronic stress exposure | Q34744471 |
| | Structural and molecular remodeling of dendritic spine substructures during long-term potentiation. | Q34798295 |
| | BDNF release is required for the behavioral actions of ketamine | Q35203597 |
| | Ketamine for depression: where do we go from here? | Q36223372 |
| | Rapid-acting glutamatergic antidepressants: the path to ketamine and beyond | Q36899381 |
| | Ketamine as a novel antidepressant: from synapse to behavior | Q36905864 |
| | GSK-3 inhibition potentiates the synaptogenic and antidepressant-like effects of subthreshold doses of ketamine | Q37172762 |
| | Depression-like phenotype by deletion of α7 nicotinic acetylcholine receptor: Role of BDNF-TrkB in nucleus accumbens. | Q37399810 |
| | Molecular and Cellular Mechanisms of Rapid-Acting Antidepressants Ketamine and Scopolamine | Q37668009 |
| | Synaptic dysfunction in depression: potential therapeutic targets | Q38050123 |
| | Regulation of hippocampal synaptic plasticity by BDNF. | Q38275797 |
| | Rho GTPase complementation underlies BDNF-dependent homo- and heterosynaptic plasticity. | Q38435800 |
| | Central administration of IGF-I and BDNF leads to long-lasting antidepressant-like effects | Q46390264 |
| | Ketamine produces lasting disruptions in encoding of sensory stimuli | Q46726606 |
| | BDNF release and signaling are required for the antidepressant actions of GLYX-13. | Q47331962 |
| | Fast-acting antidepressants rapidly stimulate ERK signaling and BDNF release in primary neuronal cultures | Q47388230 |
| | Common Neurotransmission Recruited in (R,S)-Ketamine and (2R,6R)-Hydroxynorketamine-Induced Sustained Antidepressant-like Effects. | Q47570724 |
| | Lack of Antidepressant Effects of (2R,6R)-Hydroxynorketamine in a Rat Learned Helplessness Model: Comparison with (R)-Ketamine | Q47572680 |
| | VGF function in depression and antidepressant efficacy | Q47574847 |
| | BDNF at the synapse: why location matters | Q47762461 |
| | Activity-Dependent Brain-Derived Neurotrophic Factor Release Is Required for the Rapid Antidepressant Actions of Scopolamine | Q47814036 |
| | (R)-Ketamine Shows Greater Potency and Longer Lasting Antidepressant Effects Than Its Metabolite (2R,6R)-Hydroxynorketamine. | Q47822871 |
| | Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors | Q48099473 |
| | Hypocretin (orexin) induces calcium transients in single spines postsynaptic to identified thalamocortical boutons in prefrontal slice | Q48180671 |
| | TrkB phosphorylation by Cdk5 is required for activity-dependent structural plasticity and spatial memory. | Q48336985 |
| | GLYX-13 Produces Rapid Antidepressant Responses with Key Synaptic and Behavioral Effects Distinct from Ketamine. | Q48472517 |
| | Effect of brain-derived neurotrophic factor on behavior and key members of the brain serotonin system in genetically predisposed to behavioral disorders mouse strains | Q48550443 |
| | Brain-derived neurotrophic factor produces antidepressant effects in behavioral models of depression. | Q48635095 |
| | Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex | Q48728126 |
| | Serotonin induces excitatory postsynaptic potentials in apical dendrites of neocortical pyramidal cells | Q48733614 |
| | What Are the Causes for Discrepancies of Antidepressant Actions of (2R,6R)-Hydroxynorketamine? | Q50155957 |
| | Recurrence after recovery from major depressive disorder during 15 years of observational follow-up. | Q51983388 |
| | Effects of a ketamine metabolite on synaptic NMDAR function. | Q55060170 |
| P433 | issue | 1 | |
| P1104 | number of pages | 6 | |
| P304 | page(s) | 297-302 | |
| P577 | publication date | 2018-12-17 | |
| P1433 | published in | Proceedings of the National Academy of Sciences of the United States of America | Q1146531 |
| P1476 | title | Activity-dependent brain-derived neurotrophic factor signaling is required for the antidepressant actions of (2R,6R)-hydroxynorketamine | |
| P478 | volume | 116 | |